Opdivo (Nivolumab) Patent Expiration, LOE Window & CMS Spending
Opdivo (Nivolumab) by Bristol Myers Squibb: Biologic BLA (Purple Book Regime), 0 AB generics, $269.7M 2024 CMS Part D & Medicaid spend, and $7,787 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | B125554 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $269.7M |
| 2024 Medicare Part D Spend | $50.3M |
| 2024 Medicaid Spend | $219.4M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($7,787 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.